Qube Research & Technologies LTD Supernus Pharmaceuticals, Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 160,172 shares of SUPN stock, worth $5.15 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
160,172
Previous 9,603
1567.94%
Holding current value
$5.15 Million
Previous $327,000
1210.09%
% of portfolio
0.01%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding SUPN
# of Institutions
255Shares Held
59.2MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$334 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$197 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$169 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.87MShares$92.1 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$86.1 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.72B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...